Nowadays, cardiologists should be familiar with drugs originally developed to lower blood glucose in patients with T2DM, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, given their beneficial effects on CV outcomes across various populations. Here, SLC5A2 is linked to type 2 diabetes mellitus.